C. Geisler

Articles by C. Geisler

Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035)

ByE. Kimby,C. Geisler,H. Hagberg,H. Holte,T. Lehtinen,C. Sundström

March 1st 2001

Rituximab (Rituxan) is approved for use in patients with relapsed and refractory follicular lymphoma. Considering the immune modulating effect of interferon alfa-2a (IFN [Roferon-A]) and its efficacy as a single agent in follicular lymphoma, a

Latest Updated Articles

Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035)
March 1st 2001

C. Geisler

Articles by C. Geisler

Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035)

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer

Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma

Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma

Personalized Vaccines May Have Utility Across All Lung Cancer Stages